SCHEMBL26601879

SCHEMBL26601879

Cc1cc(C(C)(C)C)c(Cl)cc1-c1cc(=O)c(C)c(C)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601604 0.87 — —
SCHEMBL26601710 0.86 — —
SCHEMBL26601568 0.84 MAPK1 (0.34) —
SCHEMBL26699083 0.84 — —
SCHEMBL26601571 0.82 — —
SCHEMBL26601575 0.82 — —
SCHEMBL26701304 0.82 — —
SCHEMBL26601569 0.82 — —
SCHEMBL26699086 0.78 GRIN2D (0.30) —
SCHEMBL26601851 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 — — US disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
Send feedback